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We report a case of pure red cell aplasia (PRCA) following
allogeneic peripheral blood stem cell transplantation
(PBSCT) for aplastic anemia with major ABO mismatch
that proved resistant to all standard treatment options
including oral prednisolone, reduction in immunosuppres-
sive treatment, erythropoietin (EPO) and Rituximab.
Finally, high-dose dexamethasone for 4 days resolved the
PRCA in our patient, 388 days after SCT and 40 days after
the first dose of dexamethasone.
A 38-year-old male with severe aplastic anemia under-
went allogeneic PBSCT in October 2003 from an HLA-
matched sibling donor. The preparative regimen consisted
of fludarabine 180mg/m2 over 6 days, ATGAM (Pharma-
cia & Upjohn Company, Kalamozoo, Michigan, USA)
40mg/kg over 4 days and busulphan 8mg/kg over 2 days.
Peripheral blood stem cell transplantation was performed
on 17 November 2003 and 18 November 2003. The
recipient was B Rh positive while the donor was A Rh
positive; other minor blood groups antigens were not
tested. The recipient’s pre-transplant anti-A IgM (saline)
titer was 1:64 and IgG (Coombs) titer was 1:128. A total
of 200ml of PBSC was infused with a cell dose
of 3.79 108mononuclear cells/kg. No manipulation of
the graft was carried out and there were no hemolytic
complications. Cyclosporine and short course methotrexate
were used as GVHD prophylaxis. An absolute neutrophil
count of4500/mm3 was achieved on day þ 14, whereas an
unsupported platelet count of 420 000/mm3 was achieved
on day þ 13.
Following the transplant the patient continued to run a
low hemoglobin (6.2–7.8 gm/dl) with a low reticulocyte
count (0.1–0.3%) despite complete donor chimerism on
VNTR analysis, and even after day þ 60 he continued to
require blood transfusions every 2 weeks.
Bone marrow examination confirmed the diagnosis of
PRCA with less than 5% erythroid precursors and the
following therapies were tried without significant reduction
in transfusion requirement or increase in reticulocyte count:
1. Oral prednisolone – 40mg daily for 6 weeks from day
þ 127 to þ 174.
2. Rituximab 375mg/m2 on day þ 183. This lead to a
fourfold reduction in IgM and IgG titer but with no
reticulocyte response.
3. Erythropoietin – 10 000 IU thrice weekly from day
þ 285 to day þ 315, 16 doses for 4 weeks, which
resulted in a decrease in anti-A titers at the end of
therapy to 1:2 IgM and and 1:4 IgG.
4. Cyclosporine was reduced with the aim of facilitating
graft-versus-recipient depletion of residual B lympho-
cytes. Dose reduction was started on day þ 240 and the
drug was stopped on day þ 326.
5. Finally, he was treated with high-dose dexamethasone
40mg intravenously for 4 days from day þ 348 to day
þ 352. He had a significant response to this therapy,
with an increase in hemoglobin from 7.3 gm/dl to
8.5 gm/dl (day þ 353) and an increase in reticulocyte
count from 0.2 to 1.2%. By day þ 374, the hemoglobin
levels had increased to 11.3 gm/dl with a reticulocyte
count of 2.4%. His blood group had converted to A Rh
positive and the anti-A titers further reduced to 1:2 IgM
and 1:2 IgG by day þ 388 (Figure 1). The hemoglobin
steadily increased to 11.9gm% with a reticulocyte count
of 1.8% on day þ 416 and remained stable until
discharge on day þ 420. He continues to be asympto-
matic with a normal hemoglobin level and reticulocyte
count, 27 months after PBSCT. Chimerism analysis,
using the tho1 marker on peripheral blood, showed
complete donor chimerism.
Pure red cell aplasia occurs in around 20% of patients
receiving transplants with major ABO incompatibility and
the post transplant increase of isoagglutinins is a significant
predictor of PRCA. Presence and persistence of isoagglu-
tinins may delay red cell engraftment and be the cause
of PRCA.1 The mechanism of prolonged PRCA after
ABO-incompatible BMT is complement-mediated immune
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Figure 1 Response of reticulocyte count and antibody titres over time.
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destruction of erythroid progenitors past the stage of BFU-E
differentiation.2 The persistence of isoagglutinins is due to
antibody-producing plasma cells of recipient origin which
are not destroyed by the conditioning regimen.3 A graft-vs-
plasma cell effect is thought to be responsible for the
rapidity of isoagglutinin disappearance after transplant-
ation.3 Immunological changes due to withdrawal of
cyclosporin A,4 or development of GVHD, are followed
by rapid resolution of delayed rbc engraftment. Many
treatment options have been reported in the literature
including high-dose EPO,5 plasma exchange, immuno-
adsorption, antithymocyte globulin, Rituximab,6 DLI, low-
dose steroids7 and bolus methylprednisolone. Evaluation of
the efficacy of any treatment is difficult because of the
eventual spontaneous resolution of PRCA post-transplant-
ation.8 In this patient, low-dose oral prednisolone, single-
dose Rituximab, erythropoietin and induction of chronic
GVHD by reduction of cyclosporine were all ineffective.
High-dose dexamethasone9 is effective in refractory
chronic ITP and this was therefore tried, with good
response in this patient.
Therapy with dexamethasone is a low cost therapeutic
option for the management of post-transplant PRCA in an
ABO-mismatched transplant.
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